Forget just checking your vision — your next eye exam might also flag your risk for a heart attack or Alzheimer's. That's the promise of oculomics, a rapidly emerging field that uses ocular biomarkers detected through retinal imaging to monitor risk for and progression of chronic systemic diseases. At Optometry's Meeting in Phoenix, Dr. Roya Attar of the University of Mississippi Medical Center made the case that optometrists are uniquely positioned to lead this shift from reactive to proactive care.

The retina, she explained, is "a living biopsy" — the only place in the body where neurons and blood vessels can be observed noninvasively. Using tools like OCT angiography (OCT-A), clinicians can already detect early diabetic retinopathy and AMD conversion before traditional methods catch them. AI is expected to supercharge this capability, enabling real-time risk tracking across patient visits.

Key Takeaways:

• Oculomics analyzes retinal biomarkers (e.g., vessel narrowing, retinal layer thinning) to assess risk for heart disease, Alzheimer's, and Parkinson's
• OCT-A can detect early diabetic retinopathy — including a larger foveal avascular zone — even when standard exams appear normal
• AI integration could allow optometrists to quantify and track systemic disease risk changes between visits

Why it matters: As chronic disease burden grows, oculomics could transform optometry into a frontline specialty for systemic disease surveillance — offering earlier interventions and more personalized care without a single incision.